Skip to main content
Erschienen in: Metabolic Brain Disease 3/2015

01.06.2015 | Research Article

Clozapine linked to nanocapsules minimizes tissue and oxidative damage to biomolecules lipids, proteins and DNA in brain of rats Wistar

verfasst von: Angélica Aparecida da Costa Güllich, Ritiéle Pinto Coelho, Bruna Cocco Pilar, Deise Jaqueline Ströher, Leandro Alex Sander Leal Galarça, Simone Machado Vieira, Jacqueline da Costa Escobar Piccoli, Sandra Elisa Haas, Vanusa Manfredini

Erschienen in: Metabolic Brain Disease | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Clozapine, atypical antipsychotic, can change oxidative stress parameters. It is known that reactive species, in excess, can have a crucial role in the etiology of diseases, as well as, can potentiating adverse effects induce by drugs. The nanocapsules have attracted attention as carriers of several drugs, with consequent reduction of adverse effects. This study aimed to evaluate histopathology and oxidative damage of biomolecules lipids, proteins and DNA in the brain of Wistar rats after treatment with nanocapsules containing clozapine. The study consisted of eight groups of male Wistar rats (n = 6): saline (SAL), free clozapine (CZP) (25 mg/Kg i.p.), blank uncoated nanocapsules (BNC), clozapine-loaded uncoated nanocapsules (CNC) (25 mg/Kg i.p.), blank chitosan-coated nanocapsules (BCSN), clozapine-loaded chitosan-coated nanocapsules (CCSN) (25 mg/Kg i.p.), blank polyethyleneglycol-coated nanocapsules (BPEGN), clozapine-loaded polyethyleneglycol-coated nanocapsules (CPEGN) (25 mg/Kg i.p.). The animals received the formulation once a day for seven consecutive days and euthanized in the eighth day. After euthanasia, the brain was collected and homogenate was processed for further analysis. The histopathology showed less brain tissue damage in nanocapsules-treated groups. The lipid peroxidation and carbonylation of proteins showed a significant increase (p < 0.05) induced by CZP. CNC and CPEGN groups obtained a reduction membrane of lipids damage and nanocapsules-treated groups showed significant improvement protein damage. CZP was able to induce genetic oxidative damage, while the nanocapsules causing less damage to DNA. The findings show that different coatings can act protecting target tissues decreasing oxidative damage, suggesting that the drug when linked to different nanocapsules is able to mitigate the harmful effects of clozapine.
Literatur
Zurück zum Zitat Abdel-Wahab BA, Abdalla ME, El-khawanki MM (2014a) Does clozapine induce myocarditis, myocardial oxidative stress and DNA damage in rats? Eur J Pharmacol 592:123–127 Abdel-Wahab BA, Abdalla ME, El-khawanki MM (2014a) Does clozapine induce myocarditis, myocardial oxidative stress and DNA damage in rats? Eur J Pharmacol 592:123–127
Zurück zum Zitat Abdel-Wahab BA et al (2014b) Protective effect of captopril against clozapine-induced myocarditis in rats: role of oxidative stress, proinflammatory cytokines and DNA damage. Chem Biol Interact 216:43–52CrossRefPubMed Abdel-Wahab BA et al (2014b) Protective effect of captopril against clozapine-induced myocarditis in rats: role of oxidative stress, proinflammatory cytokines and DNA damage. Chem Biol Interact 216:43–52CrossRefPubMed
Zurück zum Zitat Agostinho FR et al (2007) Effects of chronic haloperidol and/or clozapine on oxidative stress parameters in rat brain. Neurochem Res 32:1343–1350CrossRefPubMed Agostinho FR et al (2007) Effects of chronic haloperidol and/or clozapine on oxidative stress parameters in rat brain. Neurochem Res 32:1343–1350CrossRefPubMed
Zurück zum Zitat Atkin K et al (1996) Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 169:483–488CrossRefPubMed Atkin K et al (1996) Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 169:483–488CrossRefPubMed
Zurück zum Zitat Beck RCR et al (2005) Nanostructure-coated diclofenac-loaded microparticles: preparation, morphological characterization, in vitro release and in vivo gastrointestinal tolerance. J Braz Chem Soc 16:1233–1240CrossRef Beck RCR et al (2005) Nanostructure-coated diclofenac-loaded microparticles: preparation, morphological characterization, in vitro release and in vivo gastrointestinal tolerance. J Braz Chem Soc 16:1233–1240CrossRef
Zurück zum Zitat Beck RCR et al (2006) Nanoparticle-coated organic-inorganic microparticles: experimental design and gastrointestinal tolerance evaluation. Quim Nova 29:990–996CrossRef Beck RCR et al (2006) Nanoparticle-coated organic-inorganic microparticles: experimental design and gastrointestinal tolerance evaluation. Quim Nova 29:990–996CrossRef
Zurück zum Zitat Benvegnú DM, Barcelos RCS, Boufleur N et al (2011) Haloperidol-loaded polysorbate-coated polymeric nanocapsules increase its efficacy in the antipsychotic treatment in rats. Eur J Pharm Biopharm 77:332–336CrossRefPubMed Benvegnú DM, Barcelos RCS, Boufleur N et al (2011) Haloperidol-loaded polysorbate-coated polymeric nanocapsules increase its efficacy in the antipsychotic treatment in rats. Eur J Pharm Biopharm 77:332–336CrossRefPubMed
Zurück zum Zitat Benvegnú DM et al (2012) Haloperidol-loaded polysorbate-coated polymeric nanocapsules decrease its adverse motor side effects and oxidative stress markers in rats. Neurochem Int 61:623–631CrossRefPubMed Benvegnú DM et al (2012) Haloperidol-loaded polysorbate-coated polymeric nanocapsules decrease its adverse motor side effects and oxidative stress markers in rats. Neurochem Int 61:623–631CrossRefPubMed
Zurück zum Zitat Bergemann et al (2007) High clozapine concentrations in leukocytes in a patient who developed leukocytopenia. Prog Neuro-Psychopharmacol Biol Psychiatry 31:1068–1071CrossRef Bergemann et al (2007) High clozapine concentrations in leukocytes in a patient who developed leukocytopenia. Prog Neuro-Psychopharmacol Biol Psychiatry 31:1068–1071CrossRef
Zurück zum Zitat Bernardi A et al (2009) Indomethacin-loaded nanocápsulas treatment reduces in vivo glioblastoma growth in a rat glioma model. Cancer Lett 281:53–63CrossRefPubMed Bernardi A et al (2009) Indomethacin-loaded nanocápsulas treatment reduces in vivo glioblastoma growth in a rat glioma model. Cancer Lett 281:53–63CrossRefPubMed
Zurück zum Zitat Bernardi A et al (2010) Protective effects of indomethacin-loaded nanocapsules against oxygen-glucose deprivation in organotypic hippocampal slice cultures: involvement of neuroinflammation. Neurochem Int 57:629–636CrossRefPubMed Bernardi A et al (2010) Protective effects of indomethacin-loaded nanocapsules against oxygen-glucose deprivation in organotypic hippocampal slice cultures: involvement of neuroinflammation. Neurochem Int 57:629–636CrossRefPubMed
Zurück zum Zitat Bieniek DD et al (2011) Validação de metodologia analítica por cromatografia líquida de alta eficiência para doseamento de clozapina em nanopartículas poliméricas. Perspectiva 35(129):17–26 Bieniek DD et al (2011) Validação de metodologia analítica por cromatografia líquida de alta eficiência para doseamento de clozapina em nanopartículas poliméricas. Perspectiva 35(129):17–26
Zurück zum Zitat Brasil (2013) Ministery of Science, Tecnology e Inovation National Council for the Control of Animal Experimentation – CONCEA Brasil (2013) Ministery of Science, Tecnology e Inovation National Council for the Control of Animal Experimentation – CONCEA
Zurück zum Zitat Buur-Rasmussen B, Brosen K (1999) Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. Eur Neuropsychopharmacol 9:453–459CrossRefPubMed Buur-Rasmussen B, Brosen K (1999) Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. Eur Neuropsychopharmacol 9:453–459CrossRefPubMed
Zurück zum Zitat Correll CU, Gallego JA (2012) Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatr Clin N Am 35(3):661–681CrossRef Correll CU, Gallego JA (2012) Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatr Clin N Am 35(3):661–681CrossRef
Zurück zum Zitat Dal-Pizzol F et al (2000) Lipid peroxidation in hippocampus early and late after status epilepticus induced by pilocarpine or kainic acidin Wistar rats. Neurosci Lett 291:179–182CrossRefPubMed Dal-Pizzol F et al (2000) Lipid peroxidation in hippocampus early and late after status epilepticus induced by pilocarpine or kainic acidin Wistar rats. Neurosci Lett 291:179–182CrossRefPubMed
Zurück zum Zitat Dal-Pizzol F et al (2001) Retinol supplementation induces oxidative stress and modulates antioxidant enzyme activities in rat Sertoli cells. Free Radic Res 34:395–404CrossRefPubMed Dal-Pizzol F et al (2001) Retinol supplementation induces oxidative stress and modulates antioxidant enzyme activities in rat Sertoli cells. Free Radic Res 34:395–404CrossRefPubMed
Zurück zum Zitat Elkis H & Meltzer HY (2007) Esquizofrenia refratária. Revista Brasileira de Psiquiatria 29:II:S41-S47 Elkis H & Meltzer HY (2007) Esquizofrenia refratária. Revista Brasileira de Psiquiatria 29:II:S41-S47
Zurück zum Zitat Figueredo VM (2011) Chemical cardiomyopathies: the negative effects of medications and nonprescribed drugs on the heart. Am J Med 124:480–488CrossRefPubMed Figueredo VM (2011) Chemical cardiomyopathies: the negative effects of medications and nonprescribed drugs on the heart. Am J Med 124:480–488CrossRefPubMed
Zurück zum Zitat Flanagan R, Dunk L (2008) Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol Clin Exp 23:27–41CrossRef Flanagan R, Dunk L (2008) Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol Clin Exp 23:27–41CrossRef
Zurück zum Zitat Fontana MC et al (2011) Improved efficacy in the treatment of contact dermatitis in rats by a dermatological nanomedicine containing clobetasol propionate. Eur J Pharm Biopharm 79:241–249CrossRefPubMed Fontana MC et al (2011) Improved efficacy in the treatment of contact dermatitis in rats by a dermatological nanomedicine containing clobetasol propionate. Eur J Pharm Biopharm 79:241–249CrossRefPubMed
Zurück zum Zitat Gaszner P, Makkos Z, Kosza P (2002) Agranulocytosis during clozapine therapy. Prog Neuro-Psychopharmacol Biol Psychiatry 26:603–607CrossRef Gaszner P, Makkos Z, Kosza P (2002) Agranulocytosis during clozapine therapy. Prog Neuro-Psychopharmacol Biol Psychiatry 26:603–607CrossRef
Zurück zum Zitat Haas SJ et al (2007) Clozapineassociated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993–2003. Drug Saf 30(1):47–57CrossRefPubMed Haas SJ et al (2007) Clozapineassociated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993–2003. Drug Saf 30(1):47–57CrossRefPubMed
Zurück zum Zitat Haixiong G et al (2002) Preparation, characterization, and drug release behaviors of drug nimodipine-loaded poly (e-caprolactone)–poly (ethylene oxide)–poly ecaprolactone) amphiphilic triblock copolymer micelles. J Pharm Sci 91:1463–1473CrossRef Haixiong G et al (2002) Preparation, characterization, and drug release behaviors of drug nimodipine-loaded poly (e-caprolactone)–poly (ethylene oxide)–poly ecaprolactone) amphiphilic triblock copolymer micelles. J Pharm Sci 91:1463–1473CrossRef
Zurück zum Zitat Hogan K, Ahmed O, Markos F (2007) N-desmethylclozapine an M1 receptor agonist enhances nitric oxide’s cardiac vagal facilitation in the isolated innervated rat right atrium. Auton Neurosci 137(1–2):51–55CrossRefPubMed Hogan K, Ahmed O, Markos F (2007) N-desmethylclozapine an M1 receptor agonist enhances nitric oxide’s cardiac vagal facilitation in the isolated innervated rat right atrium. Auton Neurosci 137(1–2):51–55CrossRefPubMed
Zurück zum Zitat Husain Z et al (2006) Increased FasL expression correlates with apoptotic changes in granulocytes cultured with oxidized clozapine. Toxicol Appl Pharmacol 214:326–334CrossRefPubMed Husain Z et al (2006) Increased FasL expression correlates with apoptotic changes in granulocytes cultured with oxidized clozapine. Toxicol Appl Pharmacol 214:326–334CrossRefPubMed
Zurück zum Zitat Jann MW et al (1993) Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 24(2):161–176CrossRefPubMed Jann MW et al (1993) Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 24(2):161–176CrossRefPubMed
Zurück zum Zitat Landsiedel R et al (2009) Genotoxicity investigations on nanomaterials: methods, preparations and characterization of test material, potential artifacts and limitations – many questions, some answers. Mutat Res 681:241–258 Landsiedel R et al (2009) Genotoxicity investigations on nanomaterials: methods, preparations and characterization of test material, potential artifacts and limitations – many questions, some answers. Mutat Res 681:241–258
Zurück zum Zitat Levine RL et al (1990) Damage to proteins and lipids tissues under oxidative stress. Meth Enzymol 186:464–478 Levine RL et al (1990) Damage to proteins and lipids tissues under oxidative stress. Meth Enzymol 186:464–478
Zurück zum Zitat Lous JAEDVT et al (2003) CYP1A2 activity is an important determinant of clozapina dosage in schizophrenic patients. Eur J Pharm Sci 20:451–457CrossRef Lous JAEDVT et al (2003) CYP1A2 activity is an important determinant of clozapina dosage in schizophrenic patients. Eur J Pharm Sci 20:451–457CrossRef
Zurück zum Zitat Manu P et al (2012) When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res 134(2–3):180–186CrossRefPubMedCentralPubMed Manu P et al (2012) When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res 134(2–3):180–186CrossRefPubMedCentralPubMed
Zurück zum Zitat Mcilwain ME, Harrison J, Wheeler AJ et al (2011) Pharmacotherapy for treatment-resistant Schizophrenia. Neuropsychiatr Dis Treat 7:135–149PubMedCentralPubMed Mcilwain ME, Harrison J, Wheeler AJ et al (2011) Pharmacotherapy for treatment-resistant Schizophrenia. Neuropsychiatr Dis Treat 7:135–149PubMedCentralPubMed
Zurück zum Zitat Ohkawa H, Ohishi H, Yagi K (1979) Assay for lipid peroxide in animal tissues by thiobarbituric acid reaction. Ann Biochem 95:351–358CrossRef Ohkawa H, Ohishi H, Yagi K (1979) Assay for lipid peroxide in animal tissues by thiobarbituric acid reaction. Ann Biochem 95:351–358CrossRef
Zurück zum Zitat Pereira A, Dean B (2006) Clozapine bioactivation induces dose dependent, drug-specific toxicity of human bone marrow stromal cells: a potential in vitro system for the study of agranulocytosis. Biochem Pharmacol 72:783–793CrossRefPubMed Pereira A, Dean B (2006) Clozapine bioactivation induces dose dependent, drug-specific toxicity of human bone marrow stromal cells: a potential in vitro system for the study of agranulocytosis. Biochem Pharmacol 72:783–793CrossRefPubMed
Zurück zum Zitat Pirmohamed M, Park K (1997) Mechanism of clozapine-induced agranulocytosis. Current status of research and implications for drug development. CNS Drugs 7:139–158CrossRefPubMed Pirmohamed M, Park K (1997) Mechanism of clozapine-induced agranulocytosis. Current status of research and implications for drug development. CNS Drugs 7:139–158CrossRefPubMed
Zurück zum Zitat Polydoro M, Schröder N, Lima MNM et al (2004) Haloperidol- and clozapine-induced oxidative stress in the rat brain. Pharmacol Biochem Behav 78:751–756CrossRefPubMed Polydoro M, Schröder N, Lima MNM et al (2004) Haloperidol- and clozapine-induced oxidative stress in the rat brain. Pharmacol Biochem Behav 78:751–756CrossRefPubMed
Zurück zum Zitat Reinke A, Martins MR, Lima MS et al (2004) Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosci Lett 372:157–160CrossRefPubMed Reinke A, Martins MR, Lima MS et al (2004) Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosci Lett 372:157–160CrossRefPubMed
Zurück zum Zitat Schäfer I, Lambert M, Naber D (2004) Atypical antipsychotics in therapy refractory schizophrenia. Nervenarzt 75(1):79–91CrossRefPubMed Schäfer I, Lambert M, Naber D (2004) Atypical antipsychotics in therapy refractory schizophrenia. Nervenarzt 75(1):79–91CrossRefPubMed
Zurück zum Zitat Shrivastava A et al (2012) Atypical antipsychotics usage in long-term follow-up of first episode schizophrenia. Indian J Psychiatry 54(3):248–252CrossRefPubMedCentralPubMed Shrivastava A et al (2012) Atypical antipsychotics usage in long-term follow-up of first episode schizophrenia. Indian J Psychiatry 54(3):248–252CrossRefPubMedCentralPubMed
Zurück zum Zitat Silva CER et al (2001) Estudo-piloto com clozapina em hospital público: resultados de um ano de acompanhamento. Rev Bras Psiquiatr 23:4CrossRef Silva CER et al (2001) Estudo-piloto com clozapina em hospital público: resultados de um ano de acompanhamento. Rev Bras Psiquiatr 23:4CrossRef
Zurück zum Zitat Singh NP et al (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175:184–191CrossRefPubMed Singh NP et al (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175:184–191CrossRefPubMed
Zurück zum Zitat Wang CX et al (2009) Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model. Brain Res 1261:91–99CrossRefPubMed Wang CX et al (2009) Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model. Brain Res 1261:91–99CrossRefPubMed
Zurück zum Zitat Wu TW et al (2008) Preparation, physicochemical characterization, and antioxidant effects of quercetin nanoparticles. Int J Pharm 346:160–168CrossRefPubMed Wu TW et al (2008) Preparation, physicochemical characterization, and antioxidant effects of quercetin nanoparticles. Int J Pharm 346:160–168CrossRefPubMed
Zurück zum Zitat Xin-Hua T et al (2011) Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int J Nanomedicine 6:445–452 Xin-Hua T et al (2011) Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int J Nanomedicine 6:445–452
Metadaten
Titel
Clozapine linked to nanocapsules minimizes tissue and oxidative damage to biomolecules lipids, proteins and DNA in brain of rats Wistar
verfasst von
Angélica Aparecida da Costa Güllich
Ritiéle Pinto Coelho
Bruna Cocco Pilar
Deise Jaqueline Ströher
Leandro Alex Sander Leal Galarça
Simone Machado Vieira
Jacqueline da Costa Escobar Piccoli
Sandra Elisa Haas
Vanusa Manfredini
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Metabolic Brain Disease / Ausgabe 3/2015
Print ISSN: 0885-7490
Elektronische ISSN: 1573-7365
DOI
https://doi.org/10.1007/s11011-014-9621-5

Weitere Artikel der Ausgabe 3/2015

Metabolic Brain Disease 3/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.